Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition
Berman MH, Halper JP, Nichols TW, Jarrett H, Lundy A, Huang JH
Journal of neurology and neuroscience · 113 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Institutes of Health
- Government
- National Institute of Neurological Disorders and Stroke
- Government
- NINDS NIH HHS
- Grants
- National Institute of Neurological Disorders and Stroke (R01-NS-067435); National Institutes of Health (R01 NS067435)
Based on 3 listed funder(s).
Publication
- Published
- 2017-01-01 · J Neurol Neurosci · vol. 08 · issue 01
- Cited
- 172 citations · more than 98% of similar papers · 7.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 20 works
- Access
- Free to read
- Research areas
- Laser Applications in Dentistry and Medicine · Photoreceptor and optogenetics research · Planarian Biology and Electrostimulation
- Keywords
- Dementia, Medicine, Clinical trial, Placebo, Cognitive decline, Neuroscience, Disease, Internal medicine, Psychology, Pathology
6 authors
From US
- Marvin H. BermanQuietmind Foundation
- James P. HalperQuietmind Foundation
- Trent W Nichols · correspondingQuietmind Foundation
- Hugh JarrettQuietmind Foundation
- Alan LundyQuietmind Foundation
- Jason Haitao Huang · correspondingBaylor Scott & White Medical Center - Temple; Quietmind Foundation
Abstract
Alzheimer's disease (AD) is a common, chronic expensive debilitating neurodegenerative disease with no current treatments to prevent the physical deterioration of the brain and the consequent cognitive deficits. The current pathophysiology of Alzheimer's disease is the accumulation of neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein and amyloid-beta (Aβ) plaques. Antibody therapy of Tau and Amyloid beta, vaccines and other methods to decrease Tau and or Amyloid have not been successful after considerable pharmaceutical and biotech efforts. For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. Recently, a report on animal models using photomodulation with near infrared light to treat AD pathology in K369I tau transgenic model (K3) l engineered to develop neurofibrillary tangles, and the APPs/PSEN1dE9 transgenic model (APP/PS1) to develop amyloid plaques. Mice were treated with NIR 20 times over a four-week period and NIR treatment (600-1000 nm) was associated with a reduction in the size and number of amyloid-β plaques in the neocortex and hippocampus. We now report a small pilot double blind, placebo-controlled trial (n=11) 6 active, 3 controls and 2 dropouts assessing the effect of 28 consecutive, sixminute transcranial sessions of near infrared (NIR) stimulation using 1060-1080 nm light emitting diodes. Subjects were independently diagnosed with dementia conducted in an outpatient behavioral healthcare clinic. IRB approval was obtained through the Quietmind Foundation's institutional review Board (IRB). Results showed changes in executive functioning; clock drawing, immediate recall, praxis memory, visual attention and task switching (Trails A&B) as well as a trend of improved EEG amplitude and connectivity measures. Neuroplasticity has also been reported with NIR light stimulation and mitochondrial enhancement.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.